Public Assessment Report. Scientific discussion. Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules

Size: px
Start display at page:

Download "Public Assessment Report. Scientific discussion. Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules"

Transcription

1 Public Assessment Report Scientific discussion Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules (calcium carbonate and cholecalciferol) NL License RVG: Date: 12 March 2015 This module reflects the scientific discussion for the approval of Calcium en Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules. The marketing authorisation was granted on 3 October For information on changes after this date please refer to the module Update.

2 I. INTRODUCTION Based on the review of the quality, safety and efficacy data, the Medicines Evaluation Board (MEB) of the Netherlands has granted a marketing authorisation for Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules from Alpex Pharma (UK) Limited. The product is indicated for: Correction of combined calcium and vitamin D deficiency in elderly patients Calcium and vitamin D supplementation as an adjunct to specific therapy for osteoporosis, in patients with an established increased risk of combined calcium and vitamin D deficiency. A comprehensive description of the indications and posology is given in the SmPC. Vitamin D increases the intestinal absorption of calcium. Vitamin D supplementation corrects an insufficient vitamin D intake. Oral intake of calcium supplementation corrects a deficiency of calcium in the diet and supports the remineralisation of the skeleton if there is a lack of calcium in the diet. Oral intake of vitamin D3 corrects a vitamin D deficiency when both intake of vitamin D and sunlight exposure are inadequate. Vitamin D increases the intestinal absorption of calcium. Combined calcium and vitamin D3 administration corrects secondary senile hyperparathyroidism by counteracting the increase in parathyroid hormone (PTH) which is caused by calcium and vitamin D3 deficiency and which causes increased bone resorption. This national procedure concerns a generic application claiming essential similarity with the innovator product CaD 1000/880 citroen, effervescent granules (NL License RVG 18867), which has been registered by Will Pharma B.V. since 10 June The marketing authorisation has been granted pursuant to Article 10(1) of Directive 2001/83/EC. II. QUALITY ASPECTS II.1 Introduction Calcium and Vitamine D3 Alpex 1000 mg/880 IE contains per sachet 2500 mg calcium carbonate, corresponding to 1000 mg calcium, and cholecalciferol concentrate powder corresponding to 880 IE (equivalent to 22 µg of vitamin D3). The product is an effervescent granulate with white to off-white effervescent granules, divided in sachets. Excipients are citric acid, maltodextrin, lemon-lime flavour, sucralose, modified starch, silica colloidal anhydrous (Aerosil 200), sucrose, sodium ascorbate, medium chain triglycerides, silicon dioxide and alpha-tocopherol. The effervescent granulate is packed in in Paper/PE/Al/PE sachets. II.2 Drug Substances The active substances are calcium carbonate and cholecalciferol (vitamin D 3 ), established active substances, described in the European Pharmacopoeia (Ph.Eur.). Calcium carbonate is a well known established inorganic salt in the form of a white or almost white powder, which is practically insoluble in water. Cholecalciferol is a well known established vitamin (D 3 ) in the form of white or almost white crystals that are practically insoluble in water, but freely soluble in ethanol 96%. A powder concentrate is manufactured. 2/6

3 The CEP procedure is used for the active substances. Under the official Certification Procedures of the EDQM of the Council of Europe, manufacturers or suppliers of substances for pharmaceutical use can apply for a certificate of suitability concerning the control of the chemical purity and microbiological quality of their substance according to the corresponding specific monograph, or the evaluation of reduction of Transmissible Spongiform Encephalopathy (TSE) risk, according to the general monograph, or both. This procedure is meant to ensure that the quality of substances is guaranteed and that these substances comply with the European Pharmacopoeia. Manufacturing process A CEP has been submitted for both active substances; therefore no details on the manufacturing process have been included. Quality control of drug substance The drug substance specifications for calcium carbonate and cholecalciferol have been provided and are in compliance with the Ph.Eur. Batch analytical data demonstrating compliance with the drug substance specification have been provided for two batches of calcium carbonate, and three full-scale batches of cholecalciferol concentrate. Stability of drug substance For calcium carbonate a retest period of 1 year is claimed and supporting stability data have been provided. Stability data on the active substance cholecaliferol concentrate have been provided for three fullscale batches stored at 25 C/60% RH (48 months) and 40 C/75% RH (6 months). No trends or out of specification results were observed during the stability studies. The retest period of 60 months with the storage condition Store in the unopened original container and at a temperature of 5 C ± 3 C is acceptable. II.3 Medicinal Product Pharmaceutical development The development of the product has been described, the choice of excipients is justified and their functions explained. Since the test product is an aqueous oral solution at the time of administration and it contains active substances in the same concentrations as approved oral solutions, the bioequivalence study may waived according to the Guideline on the investigation of bioequivalence. Thus, from a chemical pharmaceutical point of view the test and reference product are bio-equivalent and no further bioequivalence studies are required. A formulation study has been performed in order to formulate an effervescent product with the following general characteristics: - aspect of the granular: white without foreign bodies; - weight of the sachets - effervescent granular which completely dissolves in about 200 ml tap water - ph of the drinking solution between 4 and 5. The MAH adequately demonstrated that the test and reference product both dissolved within 5 minutes. Overall, the pharmaceutical development has been adequately performed. Manufacturing process A non standard manufacturing process has been employed based on the amount of cholecalciferol in the final drug product. The whole process may be subdivided in three main steps: granulation, blending and packaging. The manufacturing process has been validated on three full-scale batches demonstrating that the process is adequate to manufacture the product consistently. Control of excipients Almost all of the excipients comply with the Ph.Eur. These specifications are acceptable. The lemonlime flavour has in house specifications. The specification is acceptable. A specification for the cholecalciferol concentrate has been provided and is in line with the Ph.Eur. monograph. Quality control of drug product 3/6

4 The product specification includes tests for appearance of granules, solution and sachets, ph of the solution, average weight, loss on drying, identification of calcium and cholecalciferol, assay of calcium and cholecalciferol, seal test, uniformity of dosage units and microbiological characteristics. Furthermore a forced degradation study demonstrated the stability indicating capabilities of the assay methods. There is no difference between the release and shelf-life specification. The analytical methods included in the specification have been adequately described and validated. Batch analytical data from the proposed production site have been provided on three batches, demonstrating compliance with the specification. Stability of drug product Stability data on the product has been provided on three full-scale batches stored at 25 C/60% RH (12 months) and 40 C/75% RH (6 months). The conditions used in the stability studies are according to the ICH stability guideline. The batches were stored in paper/pe/al/pe sachets. Exposure to UV light did not show degradation. Based on the submitted data the proposed shelf life of 24 months stored in a Paper/PE/Al/PE sachet with the storage condition store below 25 C is acceptable. Post approval the shelf life was extended to 36 months. Specific measures concerning the prevention of the transmission of animal spongiform encephalopathies On the CEP of cholecalciferol it is mentioned that sheep wool is used in the manufacturing of the drug substance. However, it meets the criteria described in Ph.Eur. monograph Products with risk of transmitting agents of animal spongiform encephalopathies as mentioned on the CEP. II.4 Discussion on chemical, pharmaceutical and biological aspects Based on the submitted dossier, the MEB considers that Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules has a proven chemical-pharmaceutical quality. Sufficient controls have been laid down for the active substance and finished product. III. III.1 NON-CLINICAL ASPECTS Ecotoxicity/environmental risk assessment (ERA) Since Calcium and Vitamine D3 Alpex 1000 mg/880 IE is intended for generic substitution, this will not lead to an increased exposure to the environment. An environmental risk assessment is therefore not deemed necessary. III.2 Discussion on the non-clinical aspects This product is a generic formulation of CaD 1000/880 citroen, effervescent granules which is available on the European market. Reference is made to the preclinical data obtained with the innovator product. A non-clinical overview on the pharmacology, pharmacokinetics and toxicology has been provided, which is based on up-to-date and adequate scientific literature. The overview justifies why there is no need to generate additional non-clinical pharmacology, pharmacokinetics and toxicology data. Therefore, the MEB agreed that no further non-clinical studies are required. IV. IV.1 CLINICAL ASPECTS Introduction Calcium carbonate and cholecalciferol are a well-known active substance with established efficacy and tolerability. 4/6

5 A clinical overview has been provided, which is based on scientific literature. The overview justifies why there is no need to generate additional clinical data. Therefore, the MEB agrees that no further clinical studies are required. IV.2 Pharmacokinetics Biowaiver Since the test product is an aqueous oral solution at the time of administration and it contains active substances in the same concentrations as the reference product, the bioequivalence study is waived according to the Guideline on the investigation of bioequivalence (CPMP/EWP/QWP/1401/98/Rev1). Calcium and Vitamine D3 Alpex 1000 mg/880 IE may be considered as therapeutic equivalent, with the same efficacy/safety profile as known for the active substance of the reference medicinal product. The current product can be used instead of its reference product. IV.3 Risk Management Plan The MAH did not submit a risk management plan, as it was not required at the time the application was made. This is acceptable. Both active substances are well known. The MAH has a pharmacovigilance system in place, in compliance with the applicable guidelines. IV.4 Discussion on the clinical aspects For this authorisation, reference is made to the clinical studies and experience with the innovator product CaD 1000/880 citroen, effervescent granules. No new clinical studies were conducted. The product is essentially similar to the reference product. Risk management is adequately addressed. This generic medicinal product can be used instead of the reference product. V. USER CONSULTATION The package leaflet (PL) has not been evaluated via a user consultation study. The text of the PL is the same as already approved and in force for the reference medicinal product CaD 1000/880 citroen, effervescent granules. The lay-out and style of the proposed PL is also very similar to the innovator s. The MEB agrees that additional user testing is not necessary. VI. OVERALL CONCLUSION, BENEFIT/RISK ASSESSMENT AND RECOMMENDATION Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules has a proven chemicalpharmaceutical quality and is a generic form of CaD 1000/880 citroen, effervescent granules. CaD 1000/880 citroen is a well-known medicinal product with an established favourable efficacy and safety profile Since both the reference and current product are administered as an aqueous solution, at the same concentration of active substances, no bioequivalence study is deemed necessary. The Board followed the advice of the assessors. The MEB, on the basis of the data submitted, considered that essential similarity has been demonstrated for Calcium and Vitamine D3 Alpex with the reference product, and have therefore granted a marketing authorisation. Calcium and Vitamine D3 Alpex 1000 mg/880 IE, effervescent granules was authorised in the Netherlands on 3 October /6

6 STEPS TAKEN AFTER THE FINALISATION OF THE INITIAL PROCEDURE - SUMMARY Scope Extension of the shelf-life of finished product from 24 to 36 months. Change in the batch size of the finished product up to 10-fold compared to the originally approved batch size. Type of modification Date of start of the procedure Date of end of the procedure Approval/ non approval Assessment report attached IB Approval No IA Approval No 6/6

Public Assessment Report. Scientific discussion. Imipenem/Cilastatine Stravencon 250 mg/250 mg and 500 mg/500 mg powder for solution for infusion

Public Assessment Report. Scientific discussion. Imipenem/Cilastatine Stravencon 250 mg/250 mg and 500 mg/500 mg powder for solution for infusion Public Assessment Report Scientific discussion Imipenem/Cilastatine Stravencon 250 mg/250 mg and 500 mg/500 mg powder for solution for infusion (imipenem monohydrate/cilastatin sodium) NL/H/3075/001-002/DC

More information

Public Assessment Report. Scientific discussion. Paracetamol Orifarm 500 mg film-coated tablets. (Paracetamol) DK/H/2271/001/DC.

Public Assessment Report. Scientific discussion. Paracetamol Orifarm 500 mg film-coated tablets. (Paracetamol) DK/H/2271/001/DC. Public Assessment Report Scientific discussion Paracetamol Orifarm 500 mg film-coated tablets (Paracetamol) DK/H/2271/001/DC 15 October 2014 This module reflects the scientific discussion for the approval

More information

Public Assessment Report Scientific discussion. Divisun (cholecalciferol) SE/H/1122/01/DC

Public Assessment Report Scientific discussion. Divisun (cholecalciferol) SE/H/1122/01/DC Public Assessment Report Scientific discussion Divisun (cholecalciferol) SE/H/1122/01/DC This module reflects the scientific discussion for the approval of Divisun. The procedure was finalised 2012-04-18.

More information

PL 17871/0208 UKPAR TABLE OF CONTENTS

PL 17871/0208 UKPAR TABLE OF CONTENTS Fultium-D 3 3,200 IU Capsules PL 17871/0208 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 11 Summary of Product Characteristics Page 12 Patient

More information

InVita D3 25,000 IU oral solution PL 24837/0039

InVita D3 25,000 IU oral solution PL 24837/0039 InVita D3 25,000 IU oral solution PL 24837/0039 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 5 Steps taken for assessment Page 12 Summary of Product Characteristics Page 13 Patient

More information

Public Assessment Report. Scientific discussion. Zopiclone Jubilant 7.5 mg, film-coated tablets. (zopiclone) NL/H/2914/001/MR. Date: 1 December 2014

Public Assessment Report. Scientific discussion. Zopiclone Jubilant 7.5 mg, film-coated tablets. (zopiclone) NL/H/2914/001/MR. Date: 1 December 2014 Public Assessment Report Scientific discussion Zopiclone Jubilant 7.5 mg, film-coated tablets (zopiclone) NL/H/2914/001/MR Date: 1 December 2014 This module reflects the scientific discussion for the approval

More information

Public Assessment Report. Scientific discussion. Metocell 100 mg, tablets. (metoprolol tartrate) NL License RVG:

Public Assessment Report. Scientific discussion. Metocell 100 mg, tablets. (metoprolol tartrate) NL License RVG: Public Assessment Report Scientific discussion Metocell 100 mg, tablets (metoprolol tartrate) NL License RVG: 113277 Date: 8 December 2016 This module reflects the scientific discussion for the approval

More information

Public Assessment Report. Scientific discussion. Apotel 10 mg/ml, solution for infusion. (paracetamol) NL/H/2857/001/DC

Public Assessment Report. Scientific discussion. Apotel 10 mg/ml, solution for infusion. (paracetamol) NL/H/2857/001/DC Public Assessment Report Scientific discussion Apotel 10 mg/ml, solution for infusion (paracetamol) NL/H/2857/001/DC Date: 16 December 2014 This module reflects the scientific discussion for the approval

More information

Public Assessment Report

Public Assessment Report Public Assessment Report Sodium Chloride 1 mmol/ml Oral Solution (sodium chloride) UK Licence No: PL 20346/0008 Viridian Pharma Ltd LAY SUMMARY Sodium Chloride 1 mmol/ml Oral Solution (sodium chloride)

More information

Public Assessment Report. Scientific discussion. Desloracell 5 mg, film-coated tablet. (desloratadine) NL License RVG: 112807

Public Assessment Report. Scientific discussion. Desloracell 5 mg, film-coated tablet. (desloratadine) NL License RVG: 112807 Public Assessment Report Scientific discussion Desloracell 5 mg, film-coated tablet (desloratadine) NL License RVG: 112807 Date: 6 July 2015 This module reflects the scientific discussion for the approval

More information

Paracetamol 1000 mg Effervescent Tablets PL 31388/0005

Paracetamol 1000 mg Effervescent Tablets PL 31388/0005 Paracetamol 1000 mg Effervescent Tablets PL 31388/0005 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 12 Summary of Product Characteristics Page

More information

Public Assessment Report. Scientific discussion. Amoxicilline DSM Sinochem 250 mg/5 ml and 500 mg/5 ml, powder for oral suspension

Public Assessment Report. Scientific discussion. Amoxicilline DSM Sinochem 250 mg/5 ml and 500 mg/5 ml, powder for oral suspension Public Assessment Report Scientific discussion Amoxicilline DSM Sinochem 250 mg/5 ml and 500 mg/5 ml, powder for oral suspension (amoxicillin trihydrate) NL/H/3410/001-002/DC Date: 12 December 2016 This

More information

Public Assessment Report. Scientific discussion. Paroxetine Jubilant 10 mg, 20 mg, 30 mg and 40 mg film-coated tablets.

Public Assessment Report. Scientific discussion. Paroxetine Jubilant 10 mg, 20 mg, 30 mg and 40 mg film-coated tablets. Public Assessment Report Scientific discussion Paroxetine Jubilant 10 mg, 20 mg, 30 mg and 40 mg film-coated tablets (paroxetine) NL/H/3147/001-004/DC Date: 19 July 2016 This module reflects the scientific

More information

Public Assessment Report Scientific discussion. Recikalc-D forte, 500 mg-800 IU, film-coated tablet (calcium carbonate + vitamin D 3 ) SE/H/805/03/DC

Public Assessment Report Scientific discussion. Recikalc-D forte, 500 mg-800 IU, film-coated tablet (calcium carbonate + vitamin D 3 ) SE/H/805/03/DC Public Assessment Report Scientific discussion Recikalc-D forte, 500 mg-800 IU, film-coated tablet (calcium carbonate + vitamin D 3 ) SE/H/805/03/DC This module reflects the scientific discussion for the

More information

Public Assessment Report Scientific discussion. Recikalc-D forte 500 mg-800 IU Chewable tablet (calcium carbonate + vitamin D 3 ) SE/H/805/02/DC

Public Assessment Report Scientific discussion. Recikalc-D forte 500 mg-800 IU Chewable tablet (calcium carbonate + vitamin D 3 ) SE/H/805/02/DC Public Assessment Report Scientific discussion Recikalc-D forte 500 mg-800 IU Chewable tablet (calcium carbonate + vitamin D 3 ) SE/H/805/02/DC This module reflects the scientific discussion for the approval

More information

Public Assessment Report. Scientific discussion. Linezolid Polpharma 2 mg/ml, solution for infusion. (linezolid) NL/H/2781/001/DC.

Public Assessment Report. Scientific discussion. Linezolid Polpharma 2 mg/ml, solution for infusion. (linezolid) NL/H/2781/001/DC. Public Assessment Report Scientific discussion Linezolid Polpharma 2 mg/ml, solution for infusion (linezolid) NL/H/2781/001/DC Date: 8 July 2014 This module reflects the scientific discussion for the approval

More information

DEXAMETHASONE 0.5 MG TABLETS PL 17507/0052 TABLE OF CONTENTS

DEXAMETHASONE 0.5 MG TABLETS PL 17507/0052 TABLE OF CONTENTS DEXAMETHASONE 0.5 MG TABLETS PL 17507/0052 TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 11 Steps taken after authorisation summary Page 12 Summary of

More information

Public Assessment Report. Scientific discussion. Rocuroniumbromide Hospira 10 mg/ml, solution for injection/infusion. (rocuronium bromide)

Public Assessment Report. Scientific discussion. Rocuroniumbromide Hospira 10 mg/ml, solution for injection/infusion. (rocuronium bromide) Public Assessment Report Scientific discussion Rocuroniumbromide Hospira 10 mg/ml, solution for injection/infusion (rocuronium bromide) NL/H/2812/001/DC Date: 21 July 2014 This module reflects the scientific

More information

Public Assessment Report Scientific discussion. Amoxicillin MIP (amoxicillin trihydrate) SE/H/977/01/DC

Public Assessment Report Scientific discussion. Amoxicillin MIP (amoxicillin trihydrate) SE/H/977/01/DC Public Assessment Report Scientific discussion Amoxicillin MIP (amoxicillin trihydrate) SE/H/977/01/DC This module reflects the scientific discussion for the approval of Amoxicillin-MIP. The procedure

More information

Public Assessment Report. Scientific discussion. Regiocit, solution for haemofiltration. (sodium chloride and sodium citrate) NL/H/2979/001/DC

Public Assessment Report. Scientific discussion. Regiocit, solution for haemofiltration. (sodium chloride and sodium citrate) NL/H/2979/001/DC Public Assessment Report Scientific discussion Regiocit, solution for haemofiltration (sodium chloride and sodium citrate) NL/H/2979/001/DC Date: 17 February 2015 This module reflects the scientific discussion

More information

Summary Public Assessment Report. Generics. Escitalopram Ratiopharm PT/H/0846/01-04/DC. Date:

Summary Public Assessment Report. Generics. Escitalopram Ratiopharm PT/H/0846/01-04/DC. Date: Summary Public Assessment Report Generics 5 mg, 10 mg, 15 mg, 20 mg, Orodisperdible tablets (escitalopram, oxalate) PT/H/0846/001-004/DC Date: 07-11-2014 1/7 Summary Public Assessment Report Generics Escitalopram,

More information

Public Assessment Report. Scientific discussion

Public Assessment Report. Scientific discussion Public Assessment Report Scientific discussion Levothyroxine Natrium Vale 25 mcg, 50 mcg, 75 mcg, 88 mcg, 100 mcg, 112 mcg, 125 mcg, 137 mcg, 150 mcg, 175 mcg and 200 mcg tablets (levothyroxine sodium)

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure Thorens 10 000 I.U. /ml oral drops, solution Thorens 25 000 I.U. /2.5 ml oral solution Deltius 10 000 I.U. /ml oral drops, solution Deltius 25 000 I.U.

More information

Public Assessment Report. UK National Procedure. (colecalciferol) PL 16508/0047 PL 16508/0048. ProStrakan Ltd.

Public Assessment Report. UK National Procedure. (colecalciferol) PL 16508/0047 PL 16508/0048. ProStrakan Ltd. Public Assessment Report UK National Procedure STEXEROL-D 3 1,000 IU FILM-COATED TABLETS STEXEROL-D 3 25,000 IU FILM-COATED TABLETS (colecalciferol) PL 16508/0047 PL 16508/0048 ProStrakan Ltd. 1 LAY SUMMARY

More information

Public Assessment Report. Scientific discussion. Levosimendan. Date:

Public Assessment Report. Scientific discussion. Levosimendan. Date: CMDh/223/2005 February 2014 Public Assessment Report Scientific discussion Zimino 2,5 mg/ml Konzentrat zur Herstellung einer Infusionslösung Levosimendan Date: 19.05.2015 This module reflects the scientific

More information

Summary Public Assessment Report. Generics

Summary Public Assessment Report. Generics Summary Public Assessment Report Generics 875 mg + 125 mg, Film-coated tablets (Amoxicillin Trihydrate + Potassium Clavulanate) Date: 29-12-2014 1/7 Summary Public Assessment Report Generics Amoxicillin

More information

Public Assessment Report Scientific discussion. Morfin E Consult (morphine hydrochloride)

Public Assessment Report Scientific discussion. Morfin E Consult (morphine hydrochloride) Public Assessment Report Scientific discussion Morfin E Consult (morphine hydrochloride) Asp no: 2013-0732-33, 2014-0521-22 This module reflects the scientific discussion for the approval of Morfin E Consult.

More information

Public Assessment Report Scientific discussion. Prednisolon Pilum (prednisolone) Asp no: 2013-0498

Public Assessment Report Scientific discussion. Prednisolon Pilum (prednisolone) Asp no: 2013-0498 Public Assessment Report Scientific discussion Prednisolon Pilum (prednisolone) Asp no: 2013-0498 This module reflects the scientific discussion for the approval of Prednisolon Pilum. The procedure was

More information

PUBLIC ASSESSMENT REPORT Scientific Discussion. CALTRATE VITAMIN D mg/400 IU, film-coated tablet Calcium/Vitamin D 3 FR/H/320/01/MR

PUBLIC ASSESSMENT REPORT Scientific Discussion. CALTRATE VITAMIN D mg/400 IU, film-coated tablet Calcium/Vitamin D 3 FR/H/320/01/MR Direction de l Evaluation des Médicaments et des Produits Biologiques PUBLIC ASSESSMENT REPORT Scientific Discussion CALTRATE VITAMIN D 3 600 mg/400 IU, film-coated tablet Calcium/Vitamin D 3 FR/H/320/01/MR

More information

Summary Public Assessment Report. Generics. Amoxicilina + Ácido Clavulânico Ranbaxy,

Summary Public Assessment Report. Generics. Amoxicilina + Ácido Clavulânico Ranbaxy, Summary Public Assessment Report Generics Amoxicilina + Ácido Clavulânico Ranbaxy 875 mg + 125 mg, Film-coated tablets (Amoxicillin Trihydrate + Potassium Clavulanate) Date: 29-12-2014 1/7 Summary Public

More information

Public Assessment Report Scientific discussion. Levetiracetam Ranbaxy (levetiracetam) SE/H/1004/01-04/DC

Public Assessment Report Scientific discussion. Levetiracetam Ranbaxy (levetiracetam) SE/H/1004/01-04/DC Public Assessment Report Scientific discussion Levetiracetam Ranbaxy (levetiracetam) SE/H/1004/01-04/DC This module reflects the scientific discussion for the approval of Levetiracetam Ranbaxy. The procedure

More information

Public Assessment Report. Scientific discussion. TOMIDEXOFTA 3 mg/ml + 1 mg/ml, eye drops, solution

Public Assessment Report. Scientific discussion. TOMIDEXOFTA 3 mg/ml + 1 mg/ml, eye drops, solution Public Assessment Report Scientific discussion TOMIDEXOFTA 3 mg/ml + 1 mg/ml, eye drops, solution (tobramycin 3 mg/dexamethasone sodium phosphate 1.30 mg) NL/H/2462/001/DC Date: 27 November 2015 This module

More information

Public Assessment Report Scientific discussion. Amitriptylin Abcur (amitriptyline hydrochloride) Asp no : 2013-0678 2013-0679 2013-0680

Public Assessment Report Scientific discussion. Amitriptylin Abcur (amitriptyline hydrochloride) Asp no : 2013-0678 2013-0679 2013-0680 Public Assessment Report Scientific discussion Amitriptylin Abcur (amitriptyline hydrochloride) Asp no : 2013-0678 2013-0679 2013-0680 This module reflects the scientific discussion for the approval of

More information

Public Assessment Report Scientific discussion. Prednisolon Alternova (previous Prednisolon E Consult) (prednisolone) Asp no: 2011-0921

Public Assessment Report Scientific discussion. Prednisolon Alternova (previous Prednisolon E Consult) (prednisolone) Asp no: 2011-0921 Public Assessment Report Scientific discussion Prednisolon Alternova (previous Prednisolon E Consult) (prednisolone) Asp no: 2011-0921 This module reflects the scientific discussion for the approval of

More information

Health Products Regulatory Authority IPAR IRISH MEDICINES BOARD PUBLIC ASSESSMENT REPORT FOR A MEDICINAL PRODUCT FOR HUMAN USE. Scientific discussion

Health Products Regulatory Authority IPAR IRISH MEDICINES BOARD PUBLIC ASSESSMENT REPORT FOR A MEDICINAL PRODUCT FOR HUMAN USE. Scientific discussion IPAR IRISH MEDICINES BOARD PUBLIC ASSESSMENT REPORT FOR A MEDICINAL PRODUCT FOR HUMAN USE Scientific discussion Meropenem 500 mg and 1 g, Powder for Solution for Injection or Infusion (Meropenem Trihydrate)

More information

Public Assessment Report Scientific discussion. Methotrexate Orion (methotrexate) SE/H/1422/01/DC

Public Assessment Report Scientific discussion. Methotrexate Orion (methotrexate) SE/H/1422/01/DC Public Assessment Report Scientific discussion Methotrexate Orion (methotrexate) SE/H/1422/01/DC This module reflects the scientific discussion for the approval of Methotrexate Orion. The procedure was

More information

Public Assessment Report Scientific discussion. Nicotinell Spearmint (nicotine) SE/H/1103/01-02/MR

Public Assessment Report Scientific discussion. Nicotinell Spearmint (nicotine) SE/H/1103/01-02/MR Public Assessment Report Scientific discussion Nicotinell Spearmint (nicotine) SE/H/1103/01-02/MR This module reflects the scientific discussion for the approval of Nicotinell Spearmint. The procedure

More information

Public Assessment Report Scientific discussion. Donepezil Jubilant (donepezil hydrochloride) SE/H/1172/01-02/MR

Public Assessment Report Scientific discussion. Donepezil Jubilant (donepezil hydrochloride) SE/H/1172/01-02/MR Public Assessment Report Scientific discussion Donepezil Jubilant (donepezil hydrochloride) SE/H/1172/01-02/MR This module reflects the scientific discussion for the approval of Donepezil Jubilant. The

More information

Public Assessment Report. Scientific discussion

Public Assessment Report. Scientific discussion Public Assessment Report Scientific discussion Dropodex 0.1% w/v eye drops, solution (Dexamethasone sodium phosphate) MT/H/0157/001/DC Date: 3 rd May, 2013 This module reflects the scientific discussion

More information

Public Assessment Report. Scientific discussion. Citrasol HF-CIT-PRE, solution for haemofiltration

Public Assessment Report. Scientific discussion. Citrasol HF-CIT-PRE, solution for haemofiltration Public Assessment Report Scientific discussion Citrasol HF-CIT-PRE, solution for haemofiltration (Sodium chloride, potassium chloride, magnesium chloride hexahydrate, glucose monohydrate, sodium-citrate

More information

Public Assessment Report. Scientific discussion. Voriconazol Fresenius Kabi 200 mg, powder for solution for infusion. (Voriconazole) NL/H/3248/001/DC

Public Assessment Report. Scientific discussion. Voriconazol Fresenius Kabi 200 mg, powder for solution for infusion. (Voriconazole) NL/H/3248/001/DC Public Assessment Report Scientific discussion Voriconazol Fresenius Kabi 200 mg, powder for solution for infusion (Voriconazole) NL/H/3248/001/DC Date: 21 April 2016 This module reflects the scientific

More information

Public Assessment Report Scientific discussion. Cetirizin Apofri Cetirizine hydrochloride. Asp no

Public Assessment Report Scientific discussion. Cetirizin Apofri Cetirizine hydrochloride. Asp no Public Assessment Report Scientific discussion Cetirizin Apofri Cetirizine hydrochloride Asp no 2009-1109 This module reflects the scientific discussion for the approval of Cetirizin Apofri. The procedure

More information

Public Assessment Report. Scientific discussion. Cyclofosfamide Cadiasun 500 mg, 1 g and 2 g, powder for solution for injection. (cyclophosphamide)

Public Assessment Report. Scientific discussion. Cyclofosfamide Cadiasun 500 mg, 1 g and 2 g, powder for solution for injection. (cyclophosphamide) Public Assessment Report Scientific discussion Cyclofosfamide Cadiasun 500 mg, 1 g and 2 g, powder for solution for injection (cyclophosphamide) NL/H/2814/001-003/DC Date: 3 November 2014 This module reflects

More information

HYDROCORTISONE 10 MG TABLETS

HYDROCORTISONE 10 MG TABLETS HYDROCORTISONE 10 MG TABLETS (Hydrocortisone) PL 20072/0238 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 3 Steps taken for assessment Page 12 Steps taken after authorisation summary

More information

Public Assessment Report Scientific discussion. Flucloxacillin Orion (Flucloxacillin sodium) SE/H/981/01-02/DC

Public Assessment Report Scientific discussion. Flucloxacillin Orion (Flucloxacillin sodium) SE/H/981/01-02/DC Public Assessment Report Scientific discussion Flucloxacillin Orion (Flucloxacillin sodium) SE/H/981/01-02/DC This module reflects the scientific discussion for the approval of Flucloxacillin Orion. The

More information

Public Assessment Report Scientific discussion. Folsyra Pilum (folic acid) Asp no:

Public Assessment Report Scientific discussion. Folsyra Pilum (folic acid) Asp no: Public Assessment Report Scientific discussion Folsyra Pilum (folic acid) Asp no: 2013-0667 This module reflects the scientific discussion for the approval of Folsyra Pilum. The procedure was finalised

More information

Public Assessment Report. Scientific discussion. Paracetamol Alternova 500 mg, 650 mg, 1 g (paracetamol) Asp no: 2012-0005, 2012-0006, 2012-0007

Public Assessment Report. Scientific discussion. Paracetamol Alternova 500 mg, 650 mg, 1 g (paracetamol) Asp no: 2012-0005, 2012-0006, 2012-0007 Public Assessment Report Scientific discussion Paracetamol Alternova 500 mg, 650 mg, 1 g (paracetamol) Asp no: 2012-0005, 2012-0006, 2012-0007 Applicant: E Consult ApS, Denmark This module reflects the

More information

Public Assessment Report. Scientific discussion. Tridepos (alendronate + calcium carbonate/cholecalciferol) SE/H/1463/01/DC

Public Assessment Report. Scientific discussion. Tridepos (alendronate + calcium carbonate/cholecalciferol) SE/H/1463/01/DC Public Assessment Report Scientific discussion Tridepos (alendronate + calcium carbonate/cholecalciferol) SE/H/1463/01/DC This module reflects the scientific discussion for the approval of Tridepos. The

More information

Public Assessment Report. Scientific discussion. Paracetamol Apofri 500 mg (paracetamol) Asp no: 2012-0676. Applicant: E Consult ApS, Denmark

Public Assessment Report. Scientific discussion. Paracetamol Apofri 500 mg (paracetamol) Asp no: 2012-0676. Applicant: E Consult ApS, Denmark Public Assessment Report Scientific discussion Paracetamol Apofri 500 mg (paracetamol) Asp no: 2012-0676 Applicant: E Consult ApS, Denmark This module reflects the scientific discussion for the approval

More information

Lacidipine 2 mg Film-Coated Tablets PL 08553/0502. Lacidipine 4 mg Film-Coated Tablets PL 08553/0503. UK Public Assessment Report

Lacidipine 2 mg Film-Coated Tablets PL 08553/0502. Lacidipine 4 mg Film-Coated Tablets PL 08553/0503. UK Public Assessment Report Lacidipine 2 mg Film-Coated Tablets PL 08553/0502 Lacidipine 4 mg Film-Coated Tablets PL 08553/0503 UK Public Assessment Report TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken

More information

Public Assessment Report Scientific discussion. SE/H/1349/01-07/DC Pramipexole Sandoz (pramipexole)

Public Assessment Report Scientific discussion. SE/H/1349/01-07/DC Pramipexole Sandoz (pramipexole) Public Assessment Report Scientific discussion SE/H/1349/01-07/DC Pramipexole Sandoz (pramipexole) This module reflects the scientific discussion for the approval of Pramipexole Sandoz. The procedure was

More information

Public Assessment Report Scientific discussion. Nicovel Frukt Nicovel Mint (nicotine resinate) SE/H/1195/01-04/DC

Public Assessment Report Scientific discussion. Nicovel Frukt Nicovel Mint (nicotine resinate) SE/H/1195/01-04/DC Public Assessment Report Scientific discussion Nicovel Frukt Nicovel Mint (nicotine resinate) SE/H/1195/01-04/DC This module reflects the scientific discussion for the approval of Nicovel. The procedure

More information

Public Assessment Report Scientific discussion. Valsartan/Hydrochlorothiazide Sandoz (Valsartan and Hydrochlorothiazide) SE/H/922/01-05/DC

Public Assessment Report Scientific discussion. Valsartan/Hydrochlorothiazide Sandoz (Valsartan and Hydrochlorothiazide) SE/H/922/01-05/DC Public Assessment Report Scientific discussion Valsartan/Hydrochlorothiazide Sandoz (Valsartan and Hydrochlorothiazide) SE/H/922/01-05/DC This module reflects the scientific discussion for the approval

More information

Public Assessment Report. Scientific discussion. Topiramaat Aurobindo 25 mg, 50 mg, 100 mg and 200 mg, film-coated tablets.

Public Assessment Report. Scientific discussion. Topiramaat Aurobindo 25 mg, 50 mg, 100 mg and 200 mg, film-coated tablets. Public Assessment Report Scientific discussion Topiramaat Aurobindo 25 mg, 50 mg, 100 mg and 200 mg, film-coated tablets (topiramate) NL/H/2916/001-004/MR Date: 26 May 2014 This module reflects the scientific

More information

Public Assessment Report Scientific discussion. Levetiracetam Krka (Levetiracetam) SE/H/1067/01-04/DC

Public Assessment Report Scientific discussion. Levetiracetam Krka (Levetiracetam) SE/H/1067/01-04/DC Public Assessment Report Scientific discussion Levetiracetam Krka (Levetiracetam) SE/H/1067/01-04/DC This module reflects the scientific discussion for the approval of Levetiracetam Krka. The procedure

More information

Public Assessment Report. Scientific discussion. Fluconazol Nycomed 50 mg, 100 mg, 150 mg and 200 mg Hard capsules. Fluconazole DK/H/0591/ /MR

Public Assessment Report. Scientific discussion. Fluconazol Nycomed 50 mg, 100 mg, 150 mg and 200 mg Hard capsules. Fluconazole DK/H/0591/ /MR Public Assessment Report Scientific discussion Fluconazol Nycomed 50 mg, 100 mg, 150 mg and 200 mg Hard capsules Fluconazole DK/H/0591/001-004/MR This module reflects the scientific discussion for the

More information

Public Assessment Report. Decentralised Procedure. Pemetrexed 25 mg/ml Concentrate for Solution for Infusion. (pemetrexed ditrometamol)

Public Assessment Report. Decentralised Procedure. Pemetrexed 25 mg/ml Concentrate for Solution for Infusion. (pemetrexed ditrometamol) Public Assessment Report Decentralised Procedure Pemetrexed 25 mg/ml Concentrate for Solution for Infusion (pemetrexed ditrometamol) Procedure No: UK Licence No: PL 24668/0187 Caduceus Pharma Ltd 1 LAY

More information

FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS DECENTRALISED PROCEDURE FOR A VETERINARY MEDICINAL PRODUCT VIRBAKOR 20 mg film-coated tablet for dogs Date: 03/11/2014 French agency for food, environnemental

More information

Public Assessment Report Scientific discussion. Hydrokortison CCS (hydrocortisone) SE/H/321/01/E01

Public Assessment Report Scientific discussion. Hydrokortison CCS (hydrocortisone) SE/H/321/01/E01 Public Assessment Report Scientific discussion Hydrokortison CCS (hydrocortisone) SE/H/321/01/E01 This module reflects the scientific discussion for the approval of Hydrokortison CCS. The procedure was

More information

Public Assessment Report Scientific discussion. Ibuprofen Bril Ibuprofen SE/H/1275/01-03/DC

Public Assessment Report Scientific discussion. Ibuprofen Bril Ibuprofen SE/H/1275/01-03/DC Public Assessment Report Scientific discussion Ibuprofen Bril Ibuprofen SE/H/1275/01-03/DC This module reflects the scientific discussion for the approval of Ibuprofen Bril. The procedure was finalised

More information

College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board. Graadt van Roggenweg AH Utrecht The Netherlands

College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board. Graadt van Roggenweg AH Utrecht The Netherlands College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board Graadt van Roggenweg 500 3531 AH Utrecht The Netherlands DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY

More information

Public Assessment Report Scientific discussion. Hydroxocobalamin E Consult 1 mg/ml, solution for injection (hydroxocobalamin chloride)

Public Assessment Report Scientific discussion. Hydroxocobalamin E Consult 1 mg/ml, solution for injection (hydroxocobalamin chloride) Public Assessment Report Scientific discussion Hydroxocobalamin E Consult 1 mg/ml, solution for injection (hydroxocobalamin chloride) This module reflects the scientific discussion for the approval of

More information

Decentralised Procedure. Public Assessment Report. Celecoxib-ratiopharm / Celecoxib AbZ 100/200 mg Hartkapseln. (Celecoxib) DE/H/ / /DC

Decentralised Procedure. Public Assessment Report. Celecoxib-ratiopharm / Celecoxib AbZ 100/200 mg Hartkapseln. (Celecoxib) DE/H/ / /DC Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report Celecoxib-ratiopharm / Celecoxib AbZ 100/200 mg Hartkapseln (Celecoxib) DE/H/3057-3058/001-002/DC Applicant:

More information

Public Assessment Report Scientific discussion. Oxymimer (oxytocin) SE/H/961/01-02/DC

Public Assessment Report Scientific discussion. Oxymimer (oxytocin) SE/H/961/01-02/DC Public Assessment Report Scientific discussion Oxymimer (oxytocin) SE/H/961/01-02/DC This module reflects the scientific discussion for the approval of. The procedure was finalised 2010-09-07. For information

More information

Public Assessment Report. Scientific discussion. Atorvastatine Glob 10 mg,20 mg, 40 mg, and 80 mg, film-coated tablets

Public Assessment Report. Scientific discussion. Atorvastatine Glob 10 mg,20 mg, 40 mg, and 80 mg, film-coated tablets Public Assessment Report Scientific discussion Atorvastatine Glob 10 mg,20 mg, 40 mg, and 80 mg, film-coated tablets (Atorvastatin calcium trihydrate) NL/H/2994/001-004/DC Date: 16 March 2015 This module

More information

Public Assessment Report Scientific discussion. Metoprolol Aurobindo (metoprolol tartrate) SE/H/1201/01-02/DC

Public Assessment Report Scientific discussion. Metoprolol Aurobindo (metoprolol tartrate) SE/H/1201/01-02/DC Public Assessment Report Scientific discussion Metoprolol Aurobindo (metoprolol tartrate) SE/H/1201/01-02/DC This module reflects the scientific discussion for the approval of Metoprolol Aurobindo. The

More information

Public Assessment Report Scientific discussion. Ondansetron Orifarm (ondansetron) SE/H/835/01-02/DC

Public Assessment Report Scientific discussion. Ondansetron Orifarm (ondansetron) SE/H/835/01-02/DC Public Assessment Report Scientific discussion Ondansetron Orifarm (ondansetron) SE/H/835/01-02/DC This module reflects the scientific discussion for the approval of Ondansetron Orifarm. The procedure

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure FOSFOMYCIN 3G GRANULES FOR ORAL SOLUTION Procedure No: UK Licence No: PL 31513/0007 Temapharm Sp. z.o.o. LAY SUMMARY On 17 April 2013, Czech Republic, Estonia,

More information

Public Assessment Report Scientific discussion. Elcoterol (formoterol fumarate dehydrate) SE/H/1353/01/DC

Public Assessment Report Scientific discussion. Elcoterol (formoterol fumarate dehydrate) SE/H/1353/01/DC Public Assessment Report Scientific discussion Elcoterol (formoterol fumarate dehydrate) SE/H/1353/01/DC This module reflects the scientific discussion for the approval of Elcoterol. The procedure was

More information

Public Assessment Report Scientific discussion. Fluconazole Accord (Fluconazole) SE/H/1063/01-04/DC

Public Assessment Report Scientific discussion. Fluconazole Accord (Fluconazole) SE/H/1063/01-04/DC Public Assessment Report Scientific discussion Fluconazole Accord (Fluconazole) SE/H/1063/01-04/DC This module reflects the scientific discussion for the approval of Fluconazole Accord. Please note that

More information

College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board. Graadt van Roggenweg 500 3531 AH Utrecht The Netherlands

College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board. Graadt van Roggenweg 500 3531 AH Utrecht The Netherlands College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board Graadt van Roggenweg 500 3531 AH Utrecht The Netherlands DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY

More information

Public Assessment Report Scientific discussion

Public Assessment Report Scientific discussion Public Assessment Report Scientific discussion Zonnic Mint, medicated chewing gum, 1.5 mg, 3 mg Zonnic Mint, oromucosal powder in pouch, 4 mg (nicotine) SE/H/713/01-03/DC Applicant: NicoNovum AB This module

More information

Summary Public Assessment Report. non-generics. (Acetylcysteine) PT/H/873/001/MR

Summary Public Assessment Report. non-generics. (Acetylcysteine) PT/H/873/001/MR Summary Public Assessment Report non-generics Acetilcisteína Friulchem (Acetylcysteine) Summary PAR non-generics 1/8 Acetilcisteína Friulchem Acetilcisteína Friulchem Acetylcysteine 1200 mg effervescent

More information

Decentralised Procedure. Public Assessment Report. Memantinhydrochlorid Hennig 10/20 mg Filmtabletten Memantine hydrochloride DE/H/3614/ /DC

Decentralised Procedure. Public Assessment Report. Memantinhydrochlorid Hennig 10/20 mg Filmtabletten Memantine hydrochloride DE/H/3614/ /DC Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report Memantinhydrochlorid Hennig 10/20 mg Filmtabletten Memantine hydrochloride DE/H/3614/001-002/DC Applicant:

More information

Public Assessment Report Scientific discussion. Norsed Combi D SE/H/959/01/MR

Public Assessment Report Scientific discussion. Norsed Combi D SE/H/959/01/MR Public Assessment Report Scientific discussion Norsed Combi D (risedronate sodium and calcium carbonate/cholecalciferol) SE/H/959/01/MR This module reflects the scientific discussion for the approval of

More information

Public Assessment Report Scientific discussion. Calcichew-D3 Melon, Calcichew-D3 Citron, Calcichew-D3 Melon (calcium carbonate/cholecalciferol)

Public Assessment Report Scientific discussion. Calcichew-D3 Melon, Calcichew-D3 Citron, Calcichew-D3 Melon (calcium carbonate/cholecalciferol) Public Assessment Report Scientific discussion Calcichew-D3 Melon, Calcichew-D3 Citron, Calcichew-D3 Melon (calcium carbonate/cholecalciferol) SE/H/126/06-08/DC This module reflects the scientific discussion

More information

Public Assessment Report Scientific discussion. Prednisolon mibe (prednisolone acetate) SE/H/1317/01/DC

Public Assessment Report Scientific discussion. Prednisolon mibe (prednisolone acetate) SE/H/1317/01/DC Public Assessment Report Scientific discussion Prednisolon mibe (prednisolone acetate) SE/H/1317/01/DC This module reflects the scientific discussion for the approval of Prednisolon mibe. The procedure

More information

Public Assessment Report. Scientific discussion

Public Assessment Report. Scientific discussion Public Assessment Report Scientific discussion Ésteres etílicos 90 dos ácidos ómega-3 Glenmark 1000 mg, Soft Gel Capsules (Omega-3-Acid Ethyl Esters 90) PT/H/0779/001/DC This module reflects the scientific

More information

Public Assessment Report Scientific discussion. Metoprolol Pfizer (metoprolol tartrate) SE/H/1200/01-02/DC

Public Assessment Report Scientific discussion. Metoprolol Pfizer (metoprolol tartrate) SE/H/1200/01-02/DC Public Assessment Report Scientific discussion Metoprolol Pfizer (metoprolol tartrate) SE/H/1200/01-02/DC This module reflects the scientific discussion for the approval of Metoprolol Pfizer. The procedure

More information

FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS DECENTRALISED PROCEDURE FOR A VETERINARY MEDICINAL PRODUCT Fungiconazol 200 mg tablets for dogs Canizol vet 200 mg tablets for dogs (DK, FI, IS, NO, SE,

More information

Public Assessment Report. Scientific discussion. Euplix 20 mg/20 drops (33.1 mg/ml) oral drops, solution. Paroxetine (as paroxetine mesilate)

Public Assessment Report. Scientific discussion. Euplix 20 mg/20 drops (33.1 mg/ml) oral drops, solution. Paroxetine (as paroxetine mesilate) Public Assessment Report Scientific discussion Euplix 20 mg/20 drops (33.1 mg/ml) oral drops, solution Paroxetine (as paroxetine mesilate) DK/H/0240/002/MR This module reflects the scientific discussion

More information

Public Assessment Report

Public Assessment Report Public Assessment Report Decentralised Procedure Alendronic Acid and Calcium/Cholecalciferol 70+1000mg/880IU Film-coated Tablets+Effervescent Tablets Procedure No: UK Licence No: PL 04416/1162-4 Sandoz

More information

Public Assessment Report. Decentralised Procedure

Public Assessment Report. Decentralised Procedure Public Assessment Report Decentralised Procedure Olopatadine Zentiva 1 mg/ml eye drops, solution (olopatadine hydrochloride) Procedure No: UK Licence No: PL 17780/0568 Winthrop Pharmaceuticals UK Limited

More information

Decentralised Procedure. Public Assessment Report. Pramipexol-ratiopharm 0,088/0,18/0,35/0,7 mg Tabletten. Pramipexole dihydrochloride monohydrate

Decentralised Procedure. Public Assessment Report. Pramipexol-ratiopharm 0,088/0,18/0,35/0,7 mg Tabletten. Pramipexole dihydrochloride monohydrate Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report Pramipexol-ratiopharm 0,088/0,18/0,35/0,7 mg Tabletten Pramipexole dihydrochloride monohydrate DE/H/1258/001-004/DC

More information

College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board. Graadt van Roggenweg AH Utrecht The Netherlands

College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board. Graadt van Roggenweg AH Utrecht The Netherlands College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board Graadt van Roggenweg 500 3531 AH Utrecht The Netherlands DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY

More information

Public Assessment Report Scientific discussion. Morfin Abcur (morphine hydrochloride) SE/H/1354/01/MR

Public Assessment Report Scientific discussion. Morfin Abcur (morphine hydrochloride) SE/H/1354/01/MR Public Assessment Report Scientific discussion Morfin Abcur (morphine hydrochloride) SE/H/1354/01/MR This module reflects the scientific discussion for the approval of Morfin Abcur. The procedure was finalised

More information

Public Assessment Report

Public Assessment Report Public Assessment Report SoLo Prep PL 11847/0013 MHRA: PAR SoLo Prep PL 11847/0013 1 SOLO PREP PL 11847/0013 UKPAR TABLE OF CONTENTS Page Lay Summary 3 Scientific discussion 4 Steps taken for assessment

More information

Public Assessment Report. Decentralised Procedure. CosmoCol Half 6.9 g, powder for oral solution CosmoCol Paediatric 6.9 g, powder for oral solution

Public Assessment Report. Decentralised Procedure. CosmoCol Half 6.9 g, powder for oral solution CosmoCol Paediatric 6.9 g, powder for oral solution Public Assessment Report Decentralised Procedure CosmoCol Half 6.9 g, powder for oral solution CosmoCol Paediatric 6.9 g, powder for oral solution (Macrogol, sodium chloride, sodium hydrogen carbonate

More information

FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS La Haute Marche Javené BP FOUGERES cedex FRANCE DECENTRALISED PROCEDURE

FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS La Haute Marche Javené BP FOUGERES cedex FRANCE DECENTRALISED PROCEDURE FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS La Haute Marche Javené BP 90203 35302 FOUGERES cedex FRANCE DECENTRALISED PROCEDURE FOR A VETERINARY MEDICINAL PRODUCT CLINDASEPTIN 25MG/ML ORAL SOLUTION

More information

Public Assessment Report. Scientific discussion. Ibuprofen Sandoz 200 mg and 400 mg, capsules, soft. (ibuprofen) NL/H/2810/001-002/MR

Public Assessment Report. Scientific discussion. Ibuprofen Sandoz 200 mg and 400 mg, capsules, soft. (ibuprofen) NL/H/2810/001-002/MR Public Assessment Report Scientific discussion Ibuprofen Sandoz 200 mg and 400 mg, capsules, soft (ibuprofen) 001-002/MR Date: 28 January 2016 This module reflects the scientific discussion for the approval

More information

Public Assessment Report. Scientific discussion

Public Assessment Report. Scientific discussion Public Assessment Report Scientific discussion Addaven (chromic chloride hexahydrate, copper chloride dihydrate, ferric chloride hexahydrate, manganese chloride tetrahydrate, potassium iodide, sodium fluoride,

More information

Ibuprofen 200mg Soft Capsules PL 03105/0105 UKPAR

Ibuprofen 200mg Soft Capsules PL 03105/0105 UKPAR Ibuprofen 200mg Soft Capsules PL 03105/0105 UKPAR TABLE OF CONTENTS Lay Summary Page 2 Scientific discussion Page 4 Steps taken for assessment Page 13 Summary of Product Characteristics Page 14 Patient

More information

Public Assessment Report

Public Assessment Report Public Assessment Report Decentralised Procedure Zoledronic Acid 4mg/5ml Concentrate for Solution for Infusion Procedure No: UK Licence No: PL 24598/0029 Noridem Enterprises Limited LAY SUMMARY On 25 January

More information

PUBLIC ASSESSMENT REPORT Scientific Discussion. ASPROFLASH 500mg, Coated Tablets. Acetylsalicylic acid FR/H/0482/001/DC

PUBLIC ASSESSMENT REPORT Scientific Discussion. ASPROFLASH 500mg, Coated Tablets. Acetylsalicylic acid FR/H/0482/001/DC Direction NEURHO /DP3 Neurologie-Psychiatrie-Antalgie-Rhumatologie- Pneumologie-ORL-Ophtalmologie-Stups et psychotropes PUBLIC ASSESSMENT REPORT Scientific Discussion ASPROFLASH 500mg, Coated Tablets Acetylsalicylic

More information

College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board. Graadt van Roggenweg AH Utrecht The Netherlands

College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board. Graadt van Roggenweg AH Utrecht The Netherlands College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board Graadt van Roggenweg 500 3531 AH Utrecht The Netherlands DECENTRALISED PROCEDURE PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY

More information

Decentralised Procedure. Public Assessment Report. L-Polamidon 2.5 / 5 / 20 mg Tablets Levomethadone hydrochloride DE/H/3528/ /DC

Decentralised Procedure. Public Assessment Report. L-Polamidon 2.5 / 5 / 20 mg Tablets Levomethadone hydrochloride DE/H/3528/ /DC Decentralised Procedure Public Assessment Report L-Polamidon 2.5 / 5 / 20 mg Tablets Levomethadone hydrochloride DE/H/3528/001-003/DC Applicant: Sanofi-Aventis Deutschland GmbH Reference Member State DE

More information

Public Assessment Report Scientific discussion. Valerina Forte, coated tablet. Asp no:

Public Assessment Report Scientific discussion. Valerina Forte, coated tablet. Asp no: Public Assessment Report Scientific discussion Valerina Forte, coated tablet Valeriana officinalis L., dried root, dry extract (5.25-7.5:1) ethanol 60 % Asp no: 2008-0615 This module reflects the scientific

More information

Public Assessment Report UKPAR. Fluoride 2800 ppm Toothpaste Fluoride 5000 ppm Toothpaste. (Sodium fluoride) UK Licence No: PL 20117/

Public Assessment Report UKPAR. Fluoride 2800 ppm Toothpaste Fluoride 5000 ppm Toothpaste. (Sodium fluoride) UK Licence No: PL 20117/ Public Assessment Report UKPAR Fluoride 2800 ppm Toothpaste Fluoride 5000 ppm Toothpaste (Sodium fluoride) UK Licence No: PL 20117/0239-0240 Morningside Healthcare Limited 1 LAY SUMMARY Fluoride 2800 ppm

More information

Decentralised Procedure. Public Assessment Report

Decentralised Procedure. Public Assessment Report Bundesinstitut für Arzneimittel und Medizinprodukte Decentralised Procedure Public Assessment Report ben-u-ron direkt Erdbeer/Vanille 250/500 mg Granulat in Beuteln ben-u-ron direkt Cappuccino 500/1000

More information

Public Assessment Report. Scientific discussion. Pantoprazol Beximco 20 mg and 40 mg, gastro-resistant tablets. (pantoprazole) NL/H/2751/001-002/DC

Public Assessment Report. Scientific discussion. Pantoprazol Beximco 20 mg and 40 mg, gastro-resistant tablets. (pantoprazole) NL/H/2751/001-002/DC Public Assessment Report Scientific discussion Pantoprazol Beximco 20 mg and 40 mg, gastro-resistant tablets (pantoprazole) NL/H/2751/001-002/DC Date: 27 August 2014 This module reflects the scientific

More information